Could a Week-Long heart patch catch more dangerous rhythms than a One-Day test?

NCT ID NCT06310707

Terminated Diagnosis Sponsor: Philips Clinical & Medical Affairs Global Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether wearing a small, waterproof heart monitor (ePatch) for 7 days finds more treatable heart rhythm problems than the usual 24-hour Holter monitor in people who have fainted. About 55 adults with fainting symptoms were randomly assigned to either the 7-day ePatch or a standard 24-hour monitor. The goal was to see if the longer monitoring period leads to more diagnoses that can guide treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ePatch Extended Wear Holter (7-day heart monitor)
What this could lead to: If successful, this could show that longer monitoring with ePatch finds more treatable heart rhythm problems than the standard 24-hour test.
What could go wrong: The study was terminated early with only 55 participants, so results may be limited. Longer monitoring may also pick up harmless findings that lead to unnecessary worry or tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARRYTHMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac cardiac rhythm disease Syncope syncope, familial vasovagal

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARRYTHMIA SYNCOPE

Contacts and locations

Locations

Deutsches Herzzentrum der Charité (DHZC) - Campus Benjamin Franklin

Berlin, D-12203, Germany
Hospices Civils de Lyon - Hôpital Cardiologique Louis Pradel

Bron, 69677 Cedex, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.